CN103189054B - 含有他克莫斯有效成分的缓释微丸 - Google Patents
含有他克莫斯有效成分的缓释微丸 Download PDFInfo
- Publication number
- CN103189054B CN103189054B CN201180052301.3A CN201180052301A CN103189054B CN 103189054 B CN103189054 B CN 103189054B CN 201180052301 A CN201180052301 A CN 201180052301A CN 103189054 B CN103189054 B CN 103189054B
- Authority
- CN
- China
- Prior art keywords
- slow
- tacrolimus
- hydroxypropyl methyl
- layer
- methyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title claims abstract description 84
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title claims abstract description 76
- 229960001967 tacrolimus Drugs 0.000 title claims abstract description 75
- 239000006187 pill Substances 0.000 title claims abstract description 38
- 239000004615 ingredient Substances 0.000 title claims abstract description 17
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 47
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 47
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 33
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
- 239000012748 slip agent Substances 0.000 claims description 9
- 239000007767 bonding agent Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 235000012241 calcium silicate Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229910021485 fumed silica Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000001105 regulatory effect Effects 0.000 abstract description 9
- 239000002245 particle Substances 0.000 abstract description 7
- 238000013268 sustained release Methods 0.000 abstract description 7
- 239000012730 sustained-release form Substances 0.000 abstract description 7
- 238000009826 distribution Methods 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 4
- 239000008188 pellet Substances 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000011162 core material Substances 0.000 description 15
- 230000003578 releasing effect Effects 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010828 elution Methods 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 7
- -1 with vacuum dryer Substances 0.000 description 7
- 239000000835 fiber Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001647839 Streptomyces tsukubensis Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100101778A KR101243938B1 (ko) | 2010-10-19 | 2010-10-19 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
| KR10-2010-0101778 | 2010-10-19 | ||
| PCT/KR2011/007708 WO2012053785A2 (fr) | 2010-10-19 | 2011-10-17 | Pastilles à libération prolongée contenant du tacrolimus à titre de principe actif |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103189054A CN103189054A (zh) | 2013-07-03 |
| CN103189054B true CN103189054B (zh) | 2016-06-01 |
Family
ID=45975704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180052301.3A Expired - Fee Related CN103189054B (zh) | 2010-10-19 | 2011-10-17 | 含有他克莫斯有效成分的缓释微丸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9358210B2 (fr) |
| EP (1) | EP2630956B8 (fr) |
| KR (1) | KR101243938B1 (fr) |
| CN (1) | CN103189054B (fr) |
| ES (1) | ES2727594T3 (fr) |
| TR (1) | TR201907942T4 (fr) |
| WO (1) | WO2012053785A2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9607412B2 (en) * | 2010-02-04 | 2017-03-28 | Ciena Corporation | Method for rapid determination of lowest cost wavelength routes through a photonic network based on pre-validated paths |
| CN103432099A (zh) * | 2013-08-13 | 2013-12-11 | 江苏正大清江制药有限公司 | 一种他克莫司缓释胶囊及其制备方法 |
| EP3125873B1 (fr) | 2014-04-04 | 2020-06-03 | Pharmaquest International Center, LLC | Comprimés monolithiques à libération modifiée se désintégrant, contenant des granules à libération prolongée quadri-couches |
| US20170072058A1 (en) | 2014-11-21 | 2017-03-16 | Solipharma Llc | Pharmaceutical composition containing tacrolimus and preparation methods thereof |
| CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
| US20220323367A1 (en) * | 2019-06-03 | 2022-10-13 | Synthetic Biologics, Inc. | Alkaline phosphatase formulations and uses thereof |
| JP7361004B2 (ja) * | 2020-09-08 | 2023-10-13 | 信越化学工業株式会社 | アルコール組成物の製造方法 |
| CN112641733B (zh) * | 2020-12-30 | 2022-11-22 | 北京华氏开元医药科技有限公司 | 一种西罗莫司缓释微丸及其制备方法 |
| CN116650444B (zh) * | 2023-07-31 | 2023-10-31 | 国药集团川抗制药有限公司 | 一种他克莫司缓释药物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664641A1 (fr) * | 2006-09-26 | 2008-04-10 | Astellas Pharma, Inc. | Preparation a liberation entretenue de tacrolimus |
| WO2008084698A1 (fr) * | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Composition pharmaceutique à libération entretenue de tacrolimus |
| CN101664394A (zh) * | 2009-09-25 | 2010-03-10 | 宋洪涛 | 他克莫司缓控释制剂及其制备方法 |
| KR20100060766A (ko) * | 2008-11-28 | 2010-06-07 | 주식회사 삼양사 | 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| KR100539706B1 (ko) * | 2005-01-25 | 2005-12-28 | 지엘팜텍 주식회사 | 타크로리무스 및 장용성 고분자를 함유하는 고체분산체 |
| US20100086592A1 (en) * | 2007-03-29 | 2010-04-08 | Panacea Biotec Limited. | Modified dosage forms of tacrolimus |
| US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
-
2010
- 2010-10-19 KR KR1020100101778A patent/KR101243938B1/ko active IP Right Grant
-
2011
- 2011-10-17 EP EP11834585.9A patent/EP2630956B8/fr active Active
- 2011-10-17 CN CN201180052301.3A patent/CN103189054B/zh not_active Expired - Fee Related
- 2011-10-17 WO PCT/KR2011/007708 patent/WO2012053785A2/fr active Application Filing
- 2011-10-17 TR TR2019/07942T patent/TR201907942T4/tr unknown
- 2011-10-17 ES ES11834585T patent/ES2727594T3/es active Active
- 2011-10-17 US US13/879,657 patent/US9358210B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664641A1 (fr) * | 2006-09-26 | 2008-04-10 | Astellas Pharma, Inc. | Preparation a liberation entretenue de tacrolimus |
| WO2008084698A1 (fr) * | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Composition pharmaceutique à libération entretenue de tacrolimus |
| KR20100060766A (ko) * | 2008-11-28 | 2010-06-07 | 주식회사 삼양사 | 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법 |
| CN101664394A (zh) * | 2009-09-25 | 2010-03-10 | 宋洪涛 | 他克莫司缓控释制剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 乙基纤维素水性包衣技术Ⅱ. 热处理对衣膜性质的影响;陈挺等;《中国医药工业杂志》;20001231;第31卷(第7期);摘要，第298页右栏2.1节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2727594T3 (es) | 2019-10-17 |
| EP2630956A2 (fr) | 2013-08-28 |
| EP2630956A4 (fr) | 2016-08-03 |
| KR101243938B1 (ko) | 2013-03-19 |
| US20130216624A1 (en) | 2013-08-22 |
| WO2012053785A2 (fr) | 2012-04-26 |
| TR201907942T4 (tr) | 2019-06-21 |
| CN103189054A (zh) | 2013-07-03 |
| EP2630956B8 (fr) | 2019-07-17 |
| EP2630956B1 (fr) | 2019-02-27 |
| KR20120047339A (ko) | 2012-05-14 |
| US9358210B2 (en) | 2016-06-07 |
| WO2012053785A3 (fr) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103189054B (zh) | 含有他克莫斯有效成分的缓释微丸 | |
| KR101972354B1 (ko) | 리팍시민의 고형 분산물 | |
| RU2322970C2 (ru) | Фармацевтические композиции, включающие коллоидную двуокись кремния | |
| EP3556369B1 (fr) | Composition pharmaceutique orale à libération prolongée et contrôlée d'olaparib et ses utilisations | |
| CN104274409B (zh) | 一种易于吞服的药物微球及其制备方法 | |
| CN106102716A (zh) | 雄激素受体拮抗剂的固体药物组合物 | |
| KR101264961B1 (ko) | 메칠페니데이트의 방출 제어용 약제학적 조성물 | |
| CN104902880A (zh) | 包含氢吗啡酮和纳洛酮的药物组合物 | |
| KR20090029830A (ko) | 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법 | |
| CN104414978A (zh) | 一种含有埃索美拉唑镁的肠溶微丸 | |
| WO2024027794A1 (fr) | Microsphère de masquage de goût, son procédé de préparation et son utilisation | |
| CN100475197C (zh) | 口服的可持续释放的药用组合物 | |
| CN102579408B (zh) | 盐酸多西环素双释放制剂及其制备方法 | |
| US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| EP2698150B1 (fr) | Préparation solide orale de médicament antituberculeux composé et son procédé de préparation | |
| CN115624525A (zh) | 一种他克莫司缓释药物组合物及其制备方法 | |
| CN105828827A (zh) | 一种含他克莫司的药物组合物及其制备方法 | |
| KR20070007133A (ko) | 6-머캅토퓨린의 서방형 제제 | |
| CN115192572A (zh) | 布立西坦药剂、其制备方法和应用 | |
| EP4062913B1 (fr) | Formulation orale solide d'utidélone | |
| Kanaujia et al. | Preparation, characterization and prevention of auto-oxidation of amorphous sirolimus by encapsulation in polymeric films using hot melt extrusion | |
| CN104274444B (zh) | 达比加群酯或其盐的口服双微丸药物组合物 | |
| CN111743876A (zh) | 富马酸奥比特嗪肠溶微丸及其制备方法和用途 | |
| CN102327219B (zh) | 一种埃索美拉唑镁脂质体固体制剂 | |
| CN107648231A (zh) | 右兰索拉唑药物制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170122 Address after: South Gyeonggi Do Xi Liu Quan Shan Suwon 3 hole Shengyuan District 103-405 Patentee after: Li Xiye Patentee after: Pharmaceutical Co.,Ltd. Address before: South Gyeonggi Do Xi Liu Quan Shan Suwon 3 hole Shengyuan District 103-405 Patentee before: Li Xiye |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160601 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |